JPWO2021095013A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021095013A5 JPWO2021095013A5 JP2022527730A JP2022527730A JPWO2021095013A5 JP WO2021095013 A5 JPWO2021095013 A5 JP WO2021095013A5 JP 2022527730 A JP2022527730 A JP 2022527730A JP 2022527730 A JP2022527730 A JP 2022527730A JP WO2021095013 A5 JPWO2021095013 A5 JP WO2021095013A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- cell
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934991P | 2019-11-13 | 2019-11-13 | |
| US62/934,991 | 2019-11-13 | ||
| PCT/IB2020/060723 WO2021095013A1 (en) | 2019-11-13 | 2020-11-13 | Manufacturing process for making t cells expressing chimeric antigen receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501580A JP2023501580A (ja) | 2023-01-18 |
| JPWO2021095013A5 true JPWO2021095013A5 (zh) | 2023-11-02 |
Family
ID=73598909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527730A Pending JP2023501580A (ja) | 2019-11-13 | 2020-11-13 | キメラ抗原受容体を発現するｔ細胞を作製するための製造プロセス |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210139850A1 (zh) |
| EP (1) | EP4058560A1 (zh) |
| JP (1) | JP2023501580A (zh) |
| KR (1) | KR20220097984A (zh) |
| CN (1) | CN114929862A (zh) |
| AR (1) | AR120469A1 (zh) |
| AU (1) | AU2020382219A1 (zh) |
| BR (1) | BR112022009152A2 (zh) |
| CA (1) | CA3158122A1 (zh) |
| CO (1) | CO2022006008A2 (zh) |
| IL (1) | IL292329A (zh) |
| MX (1) | MX2022005818A (zh) |
| TW (1) | TW202132333A (zh) |
| WO (1) | WO2021095013A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022064428A1 (en) * | 2020-09-23 | 2022-03-31 | Crispr Therapeutics Ag | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence |
| EP4376873A1 (en) * | 2021-07-26 | 2024-06-05 | CRISPR Therapeutics AG | Methods for manufacturing genetically engineered car-t cells |
| WO2023084399A1 (en) * | 2021-11-09 | 2023-05-19 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7 |
| US20230303713A1 (en) * | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2800811T (pt) * | 2012-05-25 | 2017-08-17 | Univ California | Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição |
| SG10201912327SA (en) * | 2012-12-12 | 2020-02-27 | Broad Inst Inc | Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation |
| US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR102668549B1 (ko) * | 2014-06-02 | 2024-05-22 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Cd19를 표적화하는 키메라 항원 수용체 |
| GB201418965D0 (zh) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| WO2016069282A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| WO2016115179A1 (en) * | 2015-01-12 | 2016-07-21 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| WO2017222398A1 (en) * | 2016-06-22 | 2017-12-28 | Cellis Sp. Z O.O. | Cellular targeted pharmaceutically active substance or label delivery system |
| ES2933961T3 (es) * | 2016-04-15 | 2023-02-15 | Memorial Sloan Kettering Cancer Center | Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados |
| EP3452499A2 (en) * | 2016-05-06 | 2019-03-13 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| DE102016211884A1 (de) | 2016-06-30 | 2018-01-04 | Zf Friedrichshafen Ag | Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug |
| EP3559214A1 (en) * | 2016-12-21 | 2019-10-30 | UCL Business PLC | Therapeutic cells |
| US11597911B2 (en) * | 2017-02-27 | 2023-03-07 | Life Technologies Corporation | Expansion of populations of T cells by the use of modified serum free media |
| WO2019097305A2 (en) | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN107392652A (zh) | 2017-06-30 | 2017-11-24 | 广州市中崎商业机器股份有限公司 | 基于收银纸背面进行针对性广告发布的系统及方法 |
| EP3665271A4 (en) * | 2017-08-08 | 2021-04-28 | Sangamo Therapeutics, Inc. | CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR |
| CN108192927A (zh) * | 2017-12-29 | 2018-06-22 | 上海海洋大学 | 一种瓯江彩鲤的基因编辑与过表达操作方法 |
| CA3090416A1 (en) * | 2018-02-09 | 2019-08-15 | Immatics US, Inc. | Methods for manufacturing t cells |
| CA3099364A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer comprising engineered t cells comprising modified chimeric antigen receptors |
-
2020
- 2020-11-13 CN CN202080087663.5A patent/CN114929862A/zh active Pending
- 2020-11-13 KR KR1020227019513A patent/KR20220097984A/ko unknown
- 2020-11-13 JP JP2022527730A patent/JP2023501580A/ja active Pending
- 2020-11-13 TW TW109139764A patent/TW202132333A/zh unknown
- 2020-11-13 EP EP20815928.5A patent/EP4058560A1/en active Pending
- 2020-11-13 BR BR112022009152A patent/BR112022009152A2/pt not_active Application Discontinuation
- 2020-11-13 WO PCT/IB2020/060723 patent/WO2021095013A1/en unknown
- 2020-11-13 MX MX2022005818A patent/MX2022005818A/es unknown
- 2020-11-13 AR ARP200103160A patent/AR120469A1/es unknown
- 2020-11-13 AU AU2020382219A patent/AU2020382219A1/en active Pending
- 2020-11-13 CA CA3158122A patent/CA3158122A1/en active Pending
- 2020-11-13 IL IL292329A patent/IL292329A/en unknown
- 2020-11-13 US US17/098,212 patent/US20210139850A1/en active Pending
-
2022
- 2022-05-09 CO CONC2022/0006008A patent/CO2022006008A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7242761B2 (ja) | キメラ抗原受容体及び他の受容体の発現に対するｔ細胞 | |
| JP2018512162A5 (zh) | ||
| CN105483083B (zh) | 双阴性t细胞的转化扩增方法 | |
| TW202146441A (zh) | 製備表現嵌合抗原受體的細胞之方法 | |
| US20210139850A1 (en) | Manufacturing process for making t cells expressing chimeric antigen receptors | |
| CN108103105A (zh) | 一种car-t细胞的制备方法、制得的car-t细胞及其应用 | |
| TW202132560A (zh) | 製備car-t細胞之方法 | |
| CN111801104A (zh) | Car-t细胞的封闭系统制造过程 | |
| KR20240007204A (ko) | 키메라 항원 수용체 및 이를 포함하는 변형된 세포 | |
| JPWO2021095012A5 (zh) | ||
| JP7043114B2 (ja) | 細胞を活性化させるための方法およびキット | |
| JPWO2021095013A5 (zh) | ||
| CN110499291A (zh) | 无血清培养制备嵌合抗原受体t细胞的方法 | |
| US20230054266A1 (en) | Method for purifying ucart cell and use thereof | |
| JP2021502816A5 (zh) | ||
| US20230126784A1 (en) | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity | |
| CN106636155A (zh) | Cd19‑car基因序列在恶性b细胞肿瘤中的应用 | |
| US20200317780A1 (en) | METHODS FOR ENHANCING TCRab+ CELL DEPLETION | |
| US20220145252A1 (en) | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors | |
| US20220249556A1 (en) | Methods for transducing immune cells | |
| WO2024140778A1 (zh) | Nkg2d工程化细胞及其组合物 | |
| JPWO2021173964A5 (zh) | ||
| WO2024008274A1 (en) | T regulatory cell modification |